Valsartan: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Valsartan": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Valsartan}} | |||
{{CMG}}; {{AE}} {{SS}} | |||
'''''For patient information about Valsartan, click [[Valsartan (patient information)|here]].''''' | |||
{{SB}} DIOVAN<sup>®</sup> | |||
{| | |||
|[[File:Valsartan02.jpg|thumb|800px]] | |||
|} | |||
[ | |||
[ | |||
== | ==Overview== | ||
'''Valsartan''' (Angiotan or Diovan) is an [[angiotensin II receptor antagonist]] (more commonly called an ARB, or angiotensin receptor blocker), with particularly high [[Affinity (pharmacology)|affinity]] for the [[Angiotensin II receptor type 1|type I (AT<sub>1</sub>) angiotensin receptor]]. By blocking the action of angiotensin, valsartan dilates blood vessels and reduces blood pressure.<ref name="Marks2007">{{cite web|url=http://www.medicinenet.com/valsartan/article.htm |title=Valsartan, Diovan |accessdate=2010-03-04 |author=Marks JW |date=2007-02-15 |publisher=MedicineNet }}</ref> In the U.S., valsartan is indicated for treatment of [[hypertension|high blood pressure]], [[congestive heart failure]] (CHF), or post-[[myocardial infarction]] (MI).<ref>{{cite web | |||
[ | | url = http://www.pharma.us.novartis.com/product/pi/pdf/diovan.pdf | ||
| title = Diovan prescribing information | |||
| publisher = Novartis | |||
}}</ref> In 2005, Valsartan was prescribed more than 12 million times in the [[United States]]{{citation needed|date=May 2012}} and global sales were approximately $6.1 billion in 2010.<ref>[http://www.novartis.com/downloads/newsroom/corporate-publications/novartis-annual-report-2010-en.pdf "Novartis Annual Report"]. Novartis. 2010. Retrieved June 15, 2011.</ref> The patents for valsartan and valsartan/hydrochlorothiazide expired in September 2012.<ref>{{cite news | |||
| title = Blockbuster Drugs That Will Go Generic Soon | |||
| date = April 29, 2011 | |||
| author = Philip Moeller | |||
| work = [[U.S.News & World Report]] | |||
| url = http://money.usnews.com/money/blogs/the-best-life/2011/04/29/blockbuster-drugs-that-will-go-generic-soon | |||
</ | }}</ref><ref>{{cite news | ||
< | | title = Novartis's Jimenez Has Blockbuster Plans For Diovan After Patent Expires | ||
| author = Eva Von Schaper | |||
| date = August 5, 2011 | |||
[http://www. | | url = http://www.bloomberg.com/news/2011-08-05/novartis-has-blockbuster-diovan-plans-after-patent-expires-1-.html | ||
< | | publisher = Bloomberg | ||
< | }}</ref> | ||
== | ==Category== | ||
Category:Amides;Angiotensin II receptor antagonists;Biphenyls;Carboxylic acids;Novartis;Category:Tetrazoles;Cardiovascular Drugs | |||
==FDA Package Insert== | |||
====Label Title==== | |||
''' [[Valsartan indications and usage|Indications and Usage]]''' | |||
'''| [[Valsartan dosage and administration|Dosage and Administration]]''' | |||
'''| [[Valsartan dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[Valsartan contraindications|Contraindications]]''' | |||
'''| [[Valsartan warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Valsartan adverse reactions|Adverse Reactions]]''' | |||
'''| [[Valsartan drug interactions|Drug Interactions]]''' | |||
'''| [[Valsartan use in specific populations|Use in Specific Populations]]''' | |||
'''| [[Valsartan overdosage|Overdosage]]''' | |||
'''| [[Valsartan description|Description]]''' | |||
'''| [[Valsartan clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Valsartan nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[Valsartan clinical studies|Clinical Studies]]''' | |||
'''| [[Valsartan how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[Valsartan patient counseling information|Patient Counseling Information]]''' | |||
'''| [[Valsartan labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
[[Angiotensin]] II is formed from [[angiotensin]] I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). [[angiotensin ]]II is the principal pressor agent of the [[renin-angiotensin system]], with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Diovan (valsartan) blocks the vasoconstrictor and aldosterone-secreting effects of [[angiotensin ]]II by selectively blocking the binding of [[angiotensin ]]II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for [[angiotensin ]]II synthesis. | |||
There is also an AT2 receptor found in many tissues, but AT2 is not known to be associated with cardiovascular homeostasis. Valsartan has much greater affinity (about 20,000-fold) for the AT1 receptor than for the AT2 receptor. The increased plasma levels of [[angiotensin ]]II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor. The primary metabolite of valsartan is essentially inactive with an affinity for the AT1 receptor about one-200th that of valsartan itself. | |||
Blockade of the [[renin-angiotensin system]] with ACE inhibitors, which inhibit the biosynthesis of [[angiotensin ]]II from [[angiotensin ]]I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of [[bradykinin]], a reaction also catalyzed by ACE. Because valsartan does not inhibit ACE (kininase II), it does not affect the response to [[bradykinin]]. Whether this difference has clinical relevance is not yet known. Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. | |||
Blockade of the [[angiotensin ]]II receptor inhibits the negative regulatory feedback of [[angiotensin ]]II on renin secretion, but the resulting increased plasma renin activity and [[angiotensin ]]II circulating levels do not overcome the effect of valsartan on blood pressure. | |||
==References== | |||
{{reflist|2}} | |||
{{Angiotensin II receptor antagonists}} | |||
[[Category:Amides]] | |||
[[Category:Angiotensin II receptor antagonists]] | |||
[[Category:Biphenyls]] | |||
[[Category:Carboxylic acids]] | |||
[[Category:Novartis]] | |||
[[Category:Tetrazoles]] | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 18:15, 24 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Valsartan, click here.
Synonyms / Brand Names: DIOVAN®
Overview
Valsartan (Angiotan or Diovan) is an angiotensin II receptor antagonist (more commonly called an ARB, or angiotensin receptor blocker), with particularly high affinity for the type I (AT1) angiotensin receptor. By blocking the action of angiotensin, valsartan dilates blood vessels and reduces blood pressure.[1] In the U.S., valsartan is indicated for treatment of high blood pressure, congestive heart failure (CHF), or post-myocardial infarction (MI).[2] In 2005, Valsartan was prescribed more than 12 million times in the United States[citation needed] and global sales were approximately $6.1 billion in 2010.[3] The patents for valsartan and valsartan/hydrochlorothiazide expired in September 2012.[4][5]
Category
Category:Amides;Angiotensin II receptor antagonists;Biphenyls;Carboxylic acids;Novartis;Category:Tetrazoles;Cardiovascular Drugs
FDA Package Insert
Label Title
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Diovan (valsartan) blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.
There is also an AT2 receptor found in many tissues, but AT2 is not known to be associated with cardiovascular homeostasis. Valsartan has much greater affinity (about 20,000-fold) for the AT1 receptor than for the AT2 receptor. The increased plasma levels of angiotensin II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor. The primary metabolite of valsartan is essentially inactive with an affinity for the AT1 receptor about one-200th that of valsartan itself.
Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because valsartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.
Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of valsartan on blood pressure.
References
- ↑ Marks JW (2007-02-15). "Valsartan, Diovan". MedicineNet. Retrieved 2010-03-04.
- ↑ "Diovan prescribing information" (PDF). Novartis.
- ↑ "Novartis Annual Report". Novartis. 2010. Retrieved June 15, 2011.
- ↑ Philip Moeller (April 29, 2011). "Blockbuster Drugs That Will Go Generic Soon". U.S.News & World Report.
- ↑ Eva Von Schaper (August 5, 2011). "Novartis's Jimenez Has Blockbuster Plans For Diovan After Patent Expires". Bloomberg.